Amphastar is reporting a shortage of Baqsimi (Glucagon Nasal Powder). This shortage has been caused by a change in the product packaging site and is estimated to end by February 27, 2025.
As part of Diabetes Canada’s ongoing efforts, we are working with
the Canadian Society of Endocrinology and Metabolism (CSEM), Health Canada, Amphastar as well as the Provincial and Territorial Drug Shortages Task Team (PT DSTT) to monitor and manage the situation. We will continue to provide updates as information becomes available (injectable glucagon remains available).
The CSEM recommends people living with diabetes and care providers:
We will continue to monitor the supply of Baqsimi and provide any new information as it becomes available. In the meantime, we encourage all affected individuals to consult with their healthcare team to discuss alternative plans for hypoglycemia management.
For further details, please visit Drug Shortages Canada or consult with your healthcare provider.
Amphastar’s client care line is 1-800-423-4136 or info@amphastar.com
As part of Diabetes Canada’s ongoing efforts, we are working with
the Canadian Society of Endocrinology and Metabolism (CSEM), Health Canada, Amphastar as well as the Provincial and Territorial Drug Shortages Task Team (PT DSTT) to monitor and manage the situation. We will continue to provide updates as information becomes available (injectable glucagon remains available).
The CSEM recommends people living with diabetes and care providers:
- Verify access and expiration dates: people living with diabetes who rely on Baqsimi are encouraged to check the expiration date of their Glucagon nasal powder and ensure it is readily accessible in case of an emergency. If the product is expired, it is recommended to consult a pharmacist to discuss whether expired medication can still be used during the shortage.
- Focus on hypoglycemia prevention: preventing hypoglycemia remains critical, particularly during this shortage of Baqsimi. People with diabetes and their caregivers should be vigilant in managing blood sugar levels to avoid severe lows that require glucagon intervention.
- Informing caregivers and family members: caregivers, family members, and others who may need to administer Baqsimi in the event of severe hypoglycemia should be informed about the current shortage and ensured they understand how to access the medication, if available.
- Alternative measures in case of severe hypoglycemia: if Baqsimi or any other glucagon treatment is not available, alternative measures should be explored:
- If the person is conscious, attempt to administer rapidly acting carbohydrates orally.
- If the individual is unconscious or unable to consume oral sugars, call for emergency medical assistance immediately.
We will continue to monitor the supply of Baqsimi and provide any new information as it becomes available. In the meantime, we encourage all affected individuals to consult with their healthcare team to discuss alternative plans for hypoglycemia management.
For further details, please visit Drug Shortages Canada or consult with your healthcare provider.
Amphastar’s client care line is 1-800-423-4136 or info@amphastar.com